source
- FDA proposes removing semaglutide, tirzepatide, liraglutide from 503B compounding listThe FDA has proposed removing the active ingredients of several popular GLP‑1 drugs from the 503B compounding list. The agency says there is no clinical need for large compounding facilities to pr…
- Avalyn Pharma launches $300M IPO, selling 16.5 million shares at $18 eachAvalyn Pharma, a Boston-based biotech, announced an initial public offering that aims to raise roughly $300 million. The company will sell more than 16.5 million shares at $18 per share and is set…